Premium
Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin
Author(s) -
TEILLAC P.,
DELAUCHECAVALLIER M. C.,
Group P. ATTALI and the DUALF
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15665.x
Subject(s) - alfuzosin , placebo , medicine , urology , muscle hypertrophy , blood pressure , heart rate , oral administration , hemodynamics , blood flow , cardiology , prostate , lower urinary tract symptoms , alternative medicine , pathology , cancer
Summary— In order to document further the onset of action of alfuzosin, a selective alpha‐1 blocker, 93 symptomatic patients with benign prostatic hypertrophy were randomly allocated to a single oral dose of either alfuzosin 1.25 mg or 2.5 mg, or placebo, after a 1‐week placebo lead‐in period. The effects on flow rates were assessed 1 h 30 min after administration. Peak and mean flow rates were significantly increased in the alfuzosin groups, as compared with placebo, in a dose‐dependent manner. After a single intake of placebo, the mean values of these 2 parameters showed little change. The effect on the cardiovascular system (heart rate and blood pressure) was mild. This study indicates that the action of alfuzosin is already present 1 h 30 min after administration.